TACALYX

Tacalyx, a spin-off from Max-Planck-Institute of Colloids and Interfaces, Potsdam/Germany (MPICI), focuses on Tumor-Associated Carbohydrate Antigens (TACAs) as novel target class for cancer treatment. The highly tumor-specific expression of TACAs results from aberrant glycosylation and promotes metastasis, angiogenesis and suppression of the immune system. Tacalyx uses the sophisticated technology of carbohydrate synthesis to synthesize highly pure TACA structures for the generation and identification of antibodies that will be developed into novel therapeutics for the treatment of cancer.